Lv21
200 积分 2024-04-17 加入
[Expert consensus on immunotherapy for small cell lung cancer (2025 edition)]
1个月前
已完结
Targeting PI3K/AKT/mTOR Signaling to Overcome Drug Resistance in Cancer
2个月前
已完结
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer
2个月前
已完结
Integrative genomic analysis of DLBCL identifies immune environments associated with bispecific antibody response
2个月前
已完结
Integrative genomic analysis of DLBCL identifies immune environments associated with bispecific antibody response
2个月前
已关闭
Integrative genomic analysis of DLBCL identifies immune environments associated with bispecific antibody response
2个月前
已关闭
A multicenter, randomized, double-blinded, placebo-controlled, phase Ⅲ study evaluating the efficacy and safety of Xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis
2个月前
已完结
Antibody‑drug conjugates in prostate cancer: Emerging strategies to enhance therapeutic index and current clinical landscape (Review)
3个月前
已完结
Biomarkers in Prostate Cancer: A Review
3个月前
已关闭
Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond
4个月前
已完结
皖公网安备34019202002308
